Lingshu Wang, Tongqing Zhou, Yi Zhang, Eun Sung Yang, Chaim A. Schramm, Wei Shi, Amarendra Pegu, Olamide K. Oloniniyi, Amy R. Henry, Samuel Darko, Sandeep R. Narpala, Christian Hatcher, David R. Martinez, Yaroslav Tsybovsky, Emily Phung, Olubukola M. Abiona, Avan Antia, Evan M. Cale, Lauren A. Chang, Misook Choe, Kizzmekia S. Corbett, Rachel L. Davis, Anthony T. DiPiazza, Ingelise J. Gordon, Sabrina Helmold Hait, Tandile Hermanus, Prudence Kgagudi, Farida Laboune, Kwanyee Leung, Tracy Liu, Rosemarie D. Mason, Alexandra F. Nazzari, Laura Novik, Sarah O’Connell, Sijy O’Dell, Adam S. Olia, Stephen D. Schmidt, Tyler Stephens, Christopher D. Stringham, Chloe Adrienna Talana, I-Ting Teng, Danielle A. Wagner, Alicia T. Widge, Baoshan Zhang, Mario Roederer, Julie E. Ledgerwood, Tracy J. Ruckwardt, Martin R. Gaudinski Nicole A. Doria-Rose, Ralph S. Baric, Barney S. Graham, Adrian B. McDermott, Daniel C. Douek, Peter D. Kwong, John R. Mascola, Nancy J. Sullivan , and John Misasi
August 13, 2021
Science
National Institutes of Health (NIH)
“Introduction: Worldwide appearance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) with increased transmissibility and resistance to therapeutic antibodies necessitates the discovery of broadly reactive antibodies. We isolated receptor binding domain (RBD) targeting antibodies that potently neutralize 23 variants…
Conclusion: Our study demonstrates that convalescent subjects previously infected with ancestral variant SARS-CoV-2 produce antibodies that cross-neutralize emerging VOCs with high potency.”
